BDR Pharma launches Nilotinib to treat Leukaemia

Sets a new standard in the treatment of Philadelphia Chromosome-positive Leukaemia BDR Pharmaceuticals has launched Nilotinib, a rare subtype of the most common childhood cancer, acute lymphoblastic leukaemia. PH+ Leukemia, encompassing Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) are infrequent and complex types of cancer that affect both children and adults. While this Philadelphia chromosome is rare in pediatric ALL, it is much more common in adult ALL. Raheel Shah, Director, BDR Pharmaceuticals said, “We are thrilled to introduce Nilotinib as a groundbreaking treatment option for patients with Philadelphia chromosome-positive leukaemia. The results from our clinical trials have demonstrated the exceptional efficacy of Nilotinib in achieving major molecular responses and significantly improving overall survival rates. We firmly believe that this drug will revolutionize the management of Ph+ leukaemia, providing new hope to patients and their families." BDR Pharma remains committed to advancing innovative therapies and enhancing the lives of patients. With the introduction of Nilotinib, the company strives to provide a game-changing solution for individuals battling Ph+ leukaemia. India's ongoing efforts in oncology healthcare demonstrate a comprehensive approach to addressing the needs of patients. By investing in cutting-edge research, fostering collaborations, and continually improving medical infrastructure, India is ensuring that patients receive the best care possible.